Prelude Therapeutics Announces Strategic Business Update
Provided By GlobeNewswire
Last update: Nov 4, 2025
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs
Pausing further clinical development of SMARCA2 selective degrader programs
Read more at globenewswire.comNASDAQ:PRLD (12/12/2025, 3:38:03 PM)
1.615
-0.01 (-0.92%)
Find more stocks in the Stock Screener
